Sensorion S.A.
PAR: ALSEN.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Amit D. Munshi
- Employees
- 63
- Headquarters
- Montpellier, France
- IPO year
- 2015
- Market cap
- €131.6M
- Website
- https://www.sensorion.com
Loading ALSEN…
Loading profile data…Frequently asked questions about ALSEN
What does Sensorion S.A. (ALSEN.PA) do?
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher...
Where does ALSEN.PA trade?
Sensorion S.A. (ALSEN.PA) trades on the Euronext Paris.
What sector is ALSEN.PA in?
Sensorion S.A. (ALSEN.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sensorion S.A.?
Amit D. Munshi is the chief executive officer of Sensorion S.A. (ALSEN.PA).
Where is Sensorion S.A. headquartered?
Sensorion S.A. is headquartered in France.
Does ALSEN.PA pay a dividend?
Sensorion S.A. (ALSEN.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALSEN.PA go public?
Sensorion S.A. (ALSEN.PA) completed its initial public offering in 2015.